FLT3抑制剂的抗肿瘤研发现状  

Research and Development Status of FLT3 Inhibitors as Antineoplastic Drugs

作　　者：姚磊[1] 宁澄清[1] 余聂芳[1] 

机构地区：[1]中南大学药学院,湖南长沙410013

出　　处：《肿瘤药学》2015年第1期1-13,共13页Anti-Tumor Pharmacy

基　　金：国家自然科学基金项目资助(30873137;30772645;81172927)

摘　　要：FLT3是一种受体型酪氨酸激酶,对造血细胞和淋巴细胞的增殖起关键作用。FLT3的异常激活与多种肿瘤特别是与急性髓性白血病的发生发展密切相关。以FLT3为靶点的小分子激酶抑制剂为多种肿瘤的治疗开辟了新途径,有许多FLT3抑制剂进入临床研究阶段,在靶向抗肿瘤领域有巨大的前景。本文主要对近年来的FLT3抑制剂的适应症及其研发状况进行综述。FLT3, a receptor tyrosine kinase, plays essential roles in hemopoiesis as well as the proliferation of lymphocyte. The abnormal activated FLT3 was closely related to the development of many cancers, especially AML. As a potential target, FLT3 was intensively studied in current pharmaceutical development. Blocking FLT3 pathway provided a promising treatment for cancer. FLT3 inhibitors were registered for clinical trials, demonstrating great efficacy against cancer. This review summarized the indication of FLT3 inhibitors and their research and development status in recent years.

关 键 词：FLT3 抑制剂 肿瘤 

分 类 号：R965.1[医药卫生—药理学] R733.3[医药卫生—药学]